Four clinical dimensions can be impaired in multiple sclerosis (MS): neurological function, cognition, emotions and fatigue. Neurological impairment, cognitive deficits and fatigue are recognised to be part of the functional handicap and deterioration of quality of life in MS patients, while the effect of emotional impairment, which includes behavioural changes and decision-making difficulties, has been less precisely defined.
In this context, neuropsychiatric co-morbidity secondary to MS is becoming an important issue in MS medical care, and therapeutic efforts strongly depend on these dimensions. Moreover, the chronic aspect of the disease, individual socio-demographic situations and the pre-morbid characteristics of each subject, as well as the brain impairment itself, influence neuropsychiatric symptoms in MS and interact with one another. Hence, it is not a surprise that subjective quality of life in MS is dependent on all of these dimensions: for example, suicidal intent of MS patients is not only related to disease-induced mood disorders such as depression, but also to the lifestyle modifications induced by MS such as alcohol abuse and individual habits such as living alone. In addition, other medical parameters such as the MS therapy itself and biographical factors such as coping abilities may influence the ability to cope with and react to such neuropsychiatric symptoms.
In this article we will present some features of these different dimensions and propose diagnostic and therapeutic cures, the latter (both pharmacological and non-pharmacological) being promising but still in their infancy. However, the most effective treatment of neuropsychiatric symptoms at the moment is early causal MS therapy. Fatigue, cognitive deficits, mood disorders and affective changes are now recognised as frequent in early MS. It is crucial to differentiate the prevalence of subtle neuropsychiatric alterations in prospective cohort studies from clinically significant impairment, which must be diagnosed in clinical practice. However, prospective studies have shed light on the frequency and potentially devastating effect of such co-morbidities, and have thus provided a rationale for efficient screening in everyday practice.
We will focus separately on the different groups of symptoms in order to outline an operational approach to each of them.
Fatigue is a multidimensional, motor-perceptive, emotional and cognitive experience, and in this sense it is highly representative of the neuropsychiatric symptoms found in MS. It can be independent of depression, but correlates highly with mood disorders, decreased levels of action control and motivational disturbances. 1 Objective fatiguerelated factors (i.e. "observable and measurable decrement in performance occurring during the repetition of a physical or mental task") can be dissociated from subjective fatigue, which is characterised by "a feeling of early exhaustion, weariness and aversion to effort", similar to (although different from) neurasthenia, as defined by the 10th
International Classification of Diseases (ICD-10). Moreover, in many ways fatigue in MS is qualitatively different from fatigue as experienced by stroke patients. It is characteristically relieved by rest and has a strong psychological impact. 2 It is not surprising, given the diversity of manifestations of this symptom in MS, that evidence-based therapy for fatigue has been very disappointing, and most clinicians agree that the most successful approach is to adapt the activities of patients. However, there seem to be some pharmacological and non-pharmacological ways to alleviate fatigue symptoms. For example, clinical experience and systematic findings from some small series have suggested that a variety of symptomatic approaches -such as dopaminergic wake-promoting agents (e.g. While the clinical profile of MS-related cognitive disturbances is characterised by a subcortical type of impairment, affecting mainly memory and executive functions, the range of neuropsychological deficits encountered in MS have been termed 'multiple disconnection syndrome', 4 indicating that the cognitive dysfunction seems to be due to manifold interruptions of different interacting fibre systems, leading to mulitiple deficits. Such deficits have also been evidenced in early MS, although the reported prevalences were variable, ranging from 25% to more than 50%. 5 Incipient cognitive deficits have also been assessed longitudinally, suggesting that such deficits might be used as predictive parameters of MS evolution and severity.
This impairment can be caused either by a general slowing of information processing or by specific alterations of memory and executive functions.
In the everyday life of MS patients, impairment of memory, attention and concentration faculties, coupled with fatigue, directly affect their personal organisation, as well as their vocational functioning and normal family role. Patients who are cognitively impaired are less likely to be working, are engaged in fewer social and vocational activities, report more sexual dysfunction, experience greater difficulty in performing household tasks and exhibit more psychopathology than cognitively intact patients. 6 Pharmacotherapy of cognitive disorders in MS has included a controlled trial of donepezil including 69 subjects; this trial found that donepezil improved verbal learning and memory compared with placebo during neuropsychological testing. 7 However, such approaches are in their infancy.
Cognitive rehabilitation in MS is still underdeveloped. Much of our knowledge of cognitive rehabilitation strategies is derived from classic studies with brain-damaged subjects who for the most part had experienced acute brain injury 8 or stroke. 9 Thus, these rehabilitation approaches deal with the management of diseases that are of an acute onset and stable course. In this case, the predictions about the dynamics of recovery and the determinants of rehabilitation of both the cognitive and physical functions may be of greater reliability, since the set of dysfunctions under treatment have a more constant relationship. In the case of MS this constancy is not given, since the occurrence of new lesions, as well as the reactivation of temporary 'silent' lesions and, ultimately, the topical expansion of a given lesion, creates a highly dynamic pattern of brain involvement, at least in the active phase of the disease. This is also reflected at the behavioural level, where a variability and fluctuation of symptoms is common. Thus, while in acute brain injury the sequelae can be restricted to particular physical and cognitive domains, which in turn can produce only time-limited consequences, in a chronic disabling disease such as MS the treatment strategy has to take into consideration the aspect of chronicity.
Nevertheless, there are some promising results, such as self-generating learning approaches 10 and training protocols using personal digital assistants. However, according to a recent meta-analysis 11 Generalised anxiety disorders seem to be 20 times more common in MS patients than in control subjects, and there is double the frequency of alcohol abuse in the former than in the latter. 12 If mood disturbance is the most commonly reported affective disorder in MS, behavioural manifestations have also been described as a variety of personality changes, although it is not possible to identify an 'MS personality'.
According to Diaz-Olavarrieta, agitation (40% occurrence), irritability (35%), apathy (20%) and disinhibition (13%) are more frequent in MS patients. 14 Behavioural manifestations, classically recognised as a variety of mood-related symptoms, include cheerfulness, optimism, denial of disability and pathological laughing. These behavioural alterations are thought to represent corollary causes of central nervous system (CNS) pathology secondary to MS, and are rather late symptoms of the disease -although they were once considered to be the hallmark of MS.
In particular, euphoric mood aberrations seem to be substrate-dependent disturbances, and tend to evolve in parallel with MS duration and severity. Other behavioural changes such as agitation, irritability, apathy and disinhibition are more frequent and also seem to play an important role in MS perceived handicap. Interestingly, such behavioural modifications not only seem to be due to the neurological characteristics of MS, but also share similarities with chronic non-neurological diseases, suggesting that the chronicity itself plays an important role. 15 Finally, MS patients, especially those individuals with a relapsingremitting disease course (RRMS), show impaired decision-making abilities. Their decreased learning proficiency in the Iowa Gambling Task suggests that poor decision-making is a consequence of impaired learning across the trials. The key point of these observations is that impaired emotional experience, more than cognitive dysfunction, is associated with impaired Iowa Gambling Task performances in RRMS 
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patients. 16 Moreover, some studies by Nagy et al. suggest that patients with RRMS show a similar performance to that observed in subjects with ventromedial prefrontal damage, namely that their decisions are guided by recent outcomes irrespective of gain or loss. 17 Given the practical consequences of impaired decision-making, the management of such problems may include behavioural as well as interpersonal approaches.
Fortunately, much emphasis has been given recently to making the diagnosis of MS as early as possible 18 Such anxious reactions may even worsen MS. 19 Adaptation to this type of progressive disability includes several intervening factors, such as cognitive impairment, timing of the impairment, pre-morbid coping mechanisms and skills, severity of the functional handicaps, availability of a supportive familial network and social resources. In particular, the development of specific adjustment strategies by individuals facing a stressful situation with problem-orientated coping seems to lead to better short-term adjustment and a lower degree of disability. 20, 21 Therefore, disease-modifying therapies, including the immunomodulators broadly used in RRMS, are mandatory to prevent neuropsychiatric symptoms in MS. The intriguing observation is that some of these drugs 
